At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 64 enrolled
Drug / intervention
Bosutinibdrug
Likely dose
Bosutinib 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF BOSUTINIB MONOTHERAPY IN JAPANESE ADULT PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA
In Brief
A Phase 2 clinical trial evaluating Bosutinib for Leukemia, Chronic Myelogenous. Completed, enrolled 64 participants across 21 sites.
Detailed Summary
Phase 2, single-arm, open-label trial. Patients will receive bosutinib for the duration of the study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia, Chronic Myelogenous
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedApr 2017
Enrollment StartMay 2017
Primary CompletionMar 2019
Study CompletionMar 2021
TodayJul 2026
First PostedApr 25, 2017
Enrollment StartMay 15, 2017
Primary CompletionMar 12, 2019
Study CompletionMar 4, 2021
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 9.2 years ago
Interventions
Bosutinibdrug
All patients will receive bosutinib at a starting dose of 400 mg QD.